Table 1.
Physical characteristics of radionuclides commonly used in brachytherapy and targeted radionuclide therapy for prostate cancer.
| Brachytherapy | |||
|---|---|---|---|
| Radionuclide | Emission | Half-Life | Mean Energy (MeV) |
| Palladium-103 | beta | 17 days | 0.021 |
| Iodine-125 | gamma | 60 days | 0.035 |
| Iridium-192 | gamma | 74 days | 0.355 |
| Cesium-131 | X-ray | 9.7 days | 0.029 |
| Targeted radionuclide therapy | |||
| Bismuth-213 | alpha | 0.03 days | 8.37 |
| Actinium-225 | alpha | 10 days | 6 |
| Radium-223 | alpha | 11.43 days | 5.64 |
| Strontium-89 | beta | 50.5 days | 1.46 |
| Samarium-153 | beta | 1.95 days | 0.80 |
| Gallium-68 | beta | 68 min | 1.83 |
| Lutetium-177 | beta | 6.7 days | 0.497 |
| Yttrium-90 | beta | 64.1 h | 2.3 |